Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms with novel therapeutic compounds in development. In this on-demand video presentation, our PAH experts will review practice-changing results presented at the 2023 ATS, ERS, and CHEST meetings to assess their potential future incorporation into clinical practice for patients with PAH.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. This activity is designed to keep healthcare professionals on top of the most recent clinical findings.

This stand alone certified AMA/ANCC/ACPE enduring video will spotlight latest advances in the management of non-small cell lung cancer harboring EGFR Mutations through a 'what you need to know' video featuring a leading expert reporting from the 2023 ESMO Congress.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Honolulu, HI, October 8-11, 2023.

Activity Summary:
Current guidelines recommend initial oral combination therapy for patients with low- or intermediate-risk pulmonary arterial hypertension (PAH) and initial combination therapy including intravenous prostacyclin for high-risk patients. These strategies are based on using regular multiparameter mortality risk assessments and proactive therapy escalation to achieve and maintain a low-risk status. This approach has been shown to slow disease progression, optimize clinical outcomes, and improve survival. Furthermore, as interest towards personalized medicine grows, a comprehensive understanding of patient phenotypes through multiomics approaches, called deep phenotyping, is needed to provide further insights on pathogenesis, diagnosis, prognosis and therapeutic outcomes.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on combination therapy and deep phenotyping featuring a PAH expert answering important commonly asked questions.

Activity Summary:
What’s New Doc? is an accredited, on-demand video presentation featuring a pulmonary arterial hypertension (PAH) expert answering important questions asked about PAH. Two AMA/ANCC/ACPE videos will be launched throughout 2023.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Pulmonary hypertension among patients with interstitial lung diseases is associated with increased morbidity, mortality, and healthcare burden. To improve outcomes, early detection and treatment of this complication among patients with ILD is an urgent priority. This slide kit will inform and guide on the latest recommendations and methodologies to screen for, detect, and accurately diagnose PH-ILD. The best-practice approaches to further treat and manage patients with PH-ILD will also be detailed. The case-based format will address knowledge and competence deficits among healthcare professionals regarding the diagnosis and treatment of PH-ILD. Overall, this module will narrow or close existing gaps in care to enable improved outcomes among patients with PH-ILD.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Recent progress in pulmonary arterial hypertension (PAH) is based on new strategies for combination therapy and on the escalation of treatments to improve the significant morbidity and mortality associated with this disease. This case-based slide kit is designed to discuss the importance of monitoring patients to determine when and how to optimally alter their PAH therapy. Case 1 discusses a newly diagnosed PAH patient with a review of diagnosis, risk assessments, and initial combination therapy strategies. Case 2 discusses a high-risk PAH patient with a review of disease progression, risk assessment and treatment escalation options.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Through patient cases, this slide kit provides learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of PAH. The module will take the learner through a complete virtual patient tour starting at the time of symptoms of PAH through diagnosis, evaluation, and how the disorder is managed. Case 1 will discuss how to manage the complications and precautions in a patient through pregnancy, labor and delivery, and the immediate postpartum period. Case 2 will discuss the common features of pediatric PAH with adult disease including the challenges that require unique approaches.

Activity Summary:
Quarterly Briefs on the Treatment for Early Lung Cancer: A Current Expert Analysis on Important Clinical Decisions is a video commentary discussing the latest study results, conference data and publications in targeted therapy and immunotherapy from the previous 3 months. The activity will be supported by downloadable slides that have the key discussion/teaching points.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Over the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension (PAH). While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Further, management decisions regarding practical issues must also be addressed. Emerging research in accurate phenotyping of PH may also improve customization of therapies and prognostication as well as to increase the homogeneity of study cohorts in clinical trials. Improvements in the care of PAH patients depends on improving clinician awareness of the latest research into new diagnostic techniques, medications, and monitoring. This on-demand presentation is designed for the multi-disciplinary medical team and addresses the practical challenges of managing patients in the new era of PAH therapy.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Current therapies for treating pulmonary hypertension aim to overcome the imbalance between vasoactive and vasodilator mediators and restore the endothelial cell function. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of PAH. This on-demand video presentation will focus on several important aspects of PAH management, including a discussion of the challenges of diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American Thoracic Society (ATS) International Conference in Washington, DC, May 19-24, 2023.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at key pulmonology conferences in 2023 through “What You Need To Know in 5-minutes” video clips. Clinical Clips are accredited for AMA/ANCC/ACPE accreditation with the completion of an evaluation and post-test.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary Hypertension (PH) is currently divided into World Health Organization (WHO) groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This on-demand video presentation presents the latest research in diagnosing and managing Groups 2-5 in patients, including a discussion of the distinctions in specific groups – CTEPH, PH-ILD, PH-COPD.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This on-demand presentation is designed using a case-based discussion on tools to improve the diagnosis of PAH and the importance of early referral.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee. Talking PAH offers various topics that can be accessed for AMA, ANCC or ACPE credit.

Continue to visit this page throughout 2023 to register for an interactive opportunity with a PAH expert through one of our live webcasts. If you are unable to make the live webcast, you will be able to access the archived video here for credit.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Through patient cases, this slide kit shows the key considerations to manage patients with PAH. Case 1 will show the patient with underlying cardiac defects and repair history and lifelong management in multidisciplinary specialty centers with expertise in pulmonary arterial hypertension - congenital heart disease (PAH-CHD). Case 2 will review the initial management of right heart failure in pulmonary hypertension (PH). Case 2 will be continued to show intensive care management.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. The Lecture Library offers various topics that can be accessed for AMA, ANCC or ACPE credit. Select your topic of interest and complete the pre/posttest and evaluation.

Continue to visit the Lecture Library series throughout 2023 to view updates from new publications and conference updates. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Activity Summary:
This AMA/ANCC/ACPE activity features a recorded discussion among three leading pulmonary hypertension (PH) experts and is designed to keep healthcare professionals on top of the most recent clinical findings.

This activity provides an expert discussion around the updated guidelines from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) as well as research presented at both ERS and CHEST 2022. These discussions provide the latest evidence for the care of patients with pulmonary hypertension based on data released from these conferences. Additionally, this activity also discusses the array of registry databases, what information has been yielded about the demographic factors, treatment, and survival of patients, as well as their limitations, which provides real-world evidence that informs clinical practice and health policy.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

Patients with PH-ILD face a dismal prognosis and are associated with reduced exercise capacity, greater need for supplemental oxygen, and a decreased quality of life. In recent years, there have been several advances in the treatment and management of PH-ILD. This slide kit will use three case scenarios to illustrate best-practice approaches to accurately diagnose PH-ILD and differentiate it from group 1 pulmonary arterial hypertension (PAH). It will also provide guidance on integrating recent progress in the treatment of PH-ILD and on the safe and effective use of approved and emerging therapy.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and often fatal illness presenting with nonspecific symptoms of dyspnea, lower extremity edema, and exercise intolerance. Most of the available drugs and FDA‐approved therapies for treating pulmonary hypertension attempt to overcome the imbalance between vasoactive and vasodilator mediators and restore the endothelial cell function. New research has identified molecular targets that mediate vasodilation, anti‐inflammatory, and antifibrotic changes within the pulmonary vasculature. This on-demand presentation will provide an updated overview of new therapeutic approaches under investigation for the treatment of PAH, as well as strategies to optimize outcomes for patients with PAH.

Activity Summary:
Talking COPD is a webcast series that highlights the very latest clinical data in chronic obstructive pulmonary disease (COPD). Slides are developed and presented by leading COPD expert physicians and further reviewed and approved by the planning committee. Talking COPD can be accessed for AMA, ANCC or ACPE credit.

COPD is a complex and heterogeneous disease, associated with significant medical, economic, and societal burden, which is predicted to increase over the coming decades. COPD imposes significant impact beyond the lungs, including on quality of life, health status, daily activities, physical activity, and sleep, as well as comorbid anxiety and depression. Given the increasing recognition of, and importance attributed to, patients’ and caregivers’ views and preferences on disease management, it is important to identify and understand their perception of COPD and the individualized impact on their lives. This understanding can help guide clinical decision-making and improve outcomes for patients with COPD.

In this on-demand webcast the learner will go through a complete virtual patient tour starting at the time of symptoms of COPD through the burden of the disease, diagnosis, evaluation, and individualized, clinically supported, guideline-based management, drawing from the GOLD Report for COPD.

Activity Summary:
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians Annual Meeting in Nashville, Tennessee, October 16-19, 2022, through a series of two ‘what you need to know in 5-minutes’ videos.

Activity Summary:
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Currently, therapies for treating pulmonary hypertension have been used alone and in combination to demonstrate improvements in quality of life and hemodynamic parameters as well as in slowing disease progression; however, beneficial effects on survival are limited. None offer a cure against PAH nor directly address the underlying cellular proliferation that leads to increased pulmonary arterial pressure, and the median survival rate remains at 61% at five years after diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in PAH. This on-demand webcast focuses on several important aspects of PAH management, including a discussion of the challenges diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.